ALT
Price
$4.39
Change
-$0.35 (-7.38%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
384.45M
28 days until earnings call
RCKT
Price
$3.20
Change
-$0.00 (-0.00%)
Updated
Jul 10, 01:43 PM (EDT)
Capitalization
344.76M
32 days until earnings call
Interact to see
Advertisement

ALT vs RCKT

Header iconALT vs RCKT Comparison
Open Charts ALT vs RCKTBanner chart's image
Altimmune
Price$4.39
Change-$0.35 (-7.38%)
Volume$87.59K
Capitalization384.45M
Rocket Pharmaceuticals
Price$3.20
Change-$0.00 (-0.00%)
Volume$300
Capitalization344.76M
ALT vs RCKT Comparison Chart in %
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. RCKT commentary
Jul 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and RCKT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 10, 2025
Stock price -- (ALT: $4.74 vs. RCKT: $3.20)
Brand notoriety: ALT and RCKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 71% vs. RCKT: 80%
Market capitalization -- ALT: $384.45M vs. RCKT: $344.76M
ALT [@Biotechnology] is valued at $384.45M. RCKT’s [@Biotechnology] market capitalization is $344.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileRCKT’s FA Score has 1 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • RCKT’s FA Score: 1 green, 4 red.
According to our system of comparison, RCKT is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while RCKT’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 5 bearish.
  • RCKT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ALT and RCKT are a good buy in the short-term.

Price Growth

ALT (@Biotechnology) experienced а -3.27% price change this week, while RCKT (@Biotechnology) price change was +11.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.89%. For the same industry, the average monthly price growth was +16.25%, and the average quarterly price growth was +20.89%.

Reported Earning Dates

ALT is expected to report earnings on Nov 11, 2025.

RCKT is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($384M) has a higher market cap than RCKT($345M). ALT YTD gains are higher at: -34.258 vs. RCKT (-74.543). ALT has higher annual earnings (EBITDA): -90.75M vs. RCKT (-246.03M). RCKT has more cash in the bank: 318M vs. ALT (150M). ALT has less debt than RCKT: ALT (1.59M) vs RCKT (25.4M). ALT has higher revenues than RCKT: ALT (20K) vs RCKT (0).
ALTRCKTALT / RCKT
Capitalization384M345M111%
EBITDA-90.75M-246.03M37%
Gain YTD-34.258-74.54346%
P/E RatioN/AN/A-
Revenue20K0-
Total Cash150M318M47%
Total Debt1.59M25.4M6%
FUNDAMENTALS RATINGS
ALT vs RCKT: Fundamental Ratings
ALT
RCKT
OUTLOOK RATING
1..100
2658
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6594
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (16) in the Biotechnology industry is significantly better than the same rating for ALT (97) in the Miscellaneous Commercial Services industry. This means that RCKT’s stock grew significantly faster than ALT’s over the last 12 months.

RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that RCKT’s stock grew similarly to ALT’s over the last 12 months.

RCKT's SMR Rating (97) in the Biotechnology industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that RCKT’s stock grew similarly to ALT’s over the last 12 months.

ALT's Price Growth Rating (65) in the Miscellaneous Commercial Services industry is in the same range as RCKT (94) in the Biotechnology industry. This means that ALT’s stock grew similarly to RCKT’s over the last 12 months.

ALT's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as RCKT (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTRCKT
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 11 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RUBLF1.430.07
+5.33%
Rubellite Energy Corp.
NAUBF25.691.16
+4.73%
National Australia Bank Ltd. (Victoria, Australia)
CSNVF21.04N/A
N/A
Corbion NV
SPCO1.00N/A
N/A
The Stephan Co.
STJPF16.10N/A
N/A
St. James Place Capital Plc.